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Abstract
Purpose Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, 
up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease 
are needed.
Methods To identify potential resistance mechanisms, we used the mouse MMTV-NIC-PTEN+/− spontaneous model of 
HER2-positive breast cancer and the pan-HER family kinase inhibitor sapatinib. Vehicle and sapatinib-treated tumors were 
evaluated by immunohistochemistry and proteomic analysis. In vitro studies were carried out to define the role of heme oxy-
genase 1 (HO-1) and autophagy in resistance to sapatinib and lapatinib, another pan-HER family kinase inhibitor.
Results Treatment of tumor-bearing MMTV-NIC-PTEN+/− mice with sapatinib resulted in delayed tumor progression and 
increased survival. However, tumors eventually progressed on treatment. Proteomic analysis identified proteins associated 
with cellular iron homeostasis as being upregulated in the sapatinib-treated tumors. This included HO-1 whose overexpres-
sion was confirmed by immunohistochemistry. Overexpression of HO-1 in HER2-expressing SKBR3 breast cancer cells 
resulted in reduced sensitivity to both pan-HER family kinase inhibitors sapatinib and lapatinib. This was associated with 
increased autophagy in the HO-1 over-expressing cells. Furthermore, increased autophagy was also seen in the sapatinib-
treated tumors. Treatment with autophagy inhibitors was able to increase the sensitivity of the HO-1 over-expressing cells 
to both lapatinib and sapatinib.
Conclusion Together these data indicate a role for HO-1-induced autophagy in resistance to pan-HER family kinase inhibitors.
Keywords HER2 · Breast cancer · HO-1 · Autophagy · Resistance
Introduction
HER2 is a member of the human epidermal growth fac-
tor receptor (EGFR) family which consists of four mem-
bers (HER1, HER2, HER3 and HER4). It is overexpressed 
in approximately 15–20% of breast cancers where it is 
associated with poor prognosis [1]. A number of HER2-tar-
geted therapies have been developed, the first of which was 
the monoclonal antibody trastuzumab [2]. In combination 
with chemotherapy, trastuzumab is currently first-line treat-
ment for patients with HER2-positive breast cancer. Other 
drugs targeting HER2 have subsequently been developed, 
including the monoclonal antibody pertuzumab and the 
small molecule tyrosine kinase inhibitors lapatinib, sapat-
inib and neratinib [3–6].
Although the introduction of HER2-targeted therapies has 
had a major impact on the treatment of the disease, resist-
ance remains a significant clinical problem. Both de novo 
and acquired resistance impact detrimentally on patient 
outcomes, reducing progression-free survival. Several 
mechanisms of resistance have been identified in preclini-
cal models, but these have proven difficult to translate into 
clinical benefit [7–9]. This is in part due to the complexity 
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and heterogeneity of the disease which is often not cap-
tured in preclinical models using established cell lines [10]. 
One alternative approach is to use genetically engineered 
mouse models which allow autochthonous tumor growth in 
immune-competent hosts [11].
For this reason, we have exploited the genetically engi-
neered MMTV-NIC (Neu-IRES-Cre) mouse model of 
HER2-driven mammary tumorigenesis [12]. In this model, 
HER2 expression is driven by MMTV-Cre in the mammary 
epithelium using a bicistronic transcript to co-express acti-
vated ErbB2/Neu (HER2) with MMTV-Cre recombinase. 
Using this approach, we have previously demonstrated that 
genetic loss of phosphatase and tensin homologue (PTEN) 
in HER2-driven mammary tumors confers resistance to the 
tyrosine kinase inhibitor sapatinib [13]. Sapatinib treatment 
resulted in tumor shrinkage in the majority of MMTV-NIC-
PTEN+/+ mice, but despite slowing tumor growth in MMTV-
NIC-PTEN+/− mice, it did not cause tumor resolution.
Using a proteomic approach, we identified heme oxyge-
nase 1 (HO-1) as being significantly upregulated in sapat-
inib-treated tumors from MMTV-NIC-PTEN+/− mice. HO-1 
is the rate limiting enzyme in the breakdown of heme groups 
into biliverdin, releasing carbon monoxide and iron in the 
process. HO-1 is also induced in response to a number of 
cellular stresses in pathological conditions where it exerts 
strong antioxidant and anti-inflammatory functions. As such, 
modulation of HO-1 expression has emerged as a potential 
therapeutic target for certain cardiovascular and neurodegen-
erative diseases where it provides a cytoprotective function 
[14]. In contrast, in the context of cancer HO-1 overexpres-
sion has been reported in a number of tumor types, includ-
ing breast, where it is associated with poor prognosis [15, 
16]. Overexpression of HO-1 in experimental models has 
been shown to increase proliferation and promote survival 
of cancer cells and tumor growth in vivo although opposing 
effects have been reported suggesting tumor type specific 
effects [15, 16]. In addition, HO-1 expression is also induced 
in response to chemo- and radiation therapy, and has been 
implicated in both drug- and therapy-induced resistance 
[17–19].
Autophagy is a catabolic process that is activated in 
response to cellular stress that allows the cell to degrade 
intracellular aggregated or misfolded proteins and dam-
aged organelles. Deregulation of autophagy in cancer can 
have both pro- and anti-survival roles and is determined by 
nutrient availability, microenvironmental stress and immune 
signals [20]. A similar paradoxical role for autophagy in 
response to therapy has been reported where induction of 
autophagy can result in either autophagic cell death or be 
activated as a protective mechanism that mediates acquired 
resistance to therapy [21]. Here we show that autophagy 
is induced in sapatinib-treated tumors in MMTV-NIC-
PTEN+/− mice and that ectopic expression of HO-1 in the 
human HER2-overexpressing cell line, SKBR3, reduces sen-
sitivity to both sapatinib and lapatinib, and confers resist-
ance in an autophagy-dependent manner.
Materials and methods
Mice
MMTV-NIC-PTEN+/− mice were generated as previously 
described [13]. All experiments were conducted in compli-
ance with UK Home Office guidelines. Nulliparous females 
were monitored twice weekly, using manual palpation, for 
tumor formation. The greatest tumor dimension and its per-
pendicular measurement were recorded, and when tumors 
had reached their maximal size (15 mm in one direction) 
as determined by Home Office regulations, mice were sac-
rificed. Tumors were then collected and fixed in 10% neu-
tral buffered formalin or flash frozen in liquid nitrogen. For 
drug studies with sapatinib (AZD8931, AstraZeneca, UK), 
treatment commenced when a tumor reached ≥ 0.1 cm3 and 
continued until mice were sacrificed due to tumor burden. 
Mice were dosed once daily by oral gavage with vehicle (1% 
Tween80 in PBS) or sapatinib (100 mg/kg in 1% Tween80 
in PBS).
Immunohistochemistry
Immunohistochemistry of formalin-fixed, paraffin-embedded 
tissues was performed as described previously [22]. Pri-
mary antibodies used were as follows: PTEN (catalogue no. 
9188; 1:200; Cell Signaling, MA, USA), phospho-Akt (Ser 
473; catalogue no. 4060; 1:50; Cell Signaling, MA, USA), 
pErk1/2 (Thr202/Tyr204; catalogue no. 4370; 1:250; Cell 
Signaling, MA, USA), HO-1 (catalogue no. ab13248; 1:250; 
Abcam, Cambridge, UK), NRF2 (catalogue no. ab31163; 
1:100; Abcam, Cambridge, UK), LC3-B (catalogue no. 
0231-100; 1:100; Nanotools, Germany), p62 (catalogue 
no. BMLPW9860; 1:1000; Enzo Life Sciences, NY, USA). 
Staining was scored using Definiens Architect Tissue Stu-
dio software (Definiens, Germany) and statistical analysis, 
comparing percentage of positively stained cells, performed 
using Prism (GraphPad, CA, USA).
Proteomics
Tumors from MMTV-NIC-PTEN+/− mice were homog-
enized in 8  M urea, 50  mM ammonium bicarbonate 
with protease and phosphatase inhibitors. Samples were 
denatured with 8 mM dithiothreitol (10 min; 50 °C) and 
alkylated with 16 mM iodoacetamide (10 min; 37 °C). Sam-
ples were digested with trypsin overnight at 37 °C (1:200 
enzyme:protein). Peptide extracts were then cleaned on stage 
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tips before being analysed on a Thermo RSLC 3000 Nano 
with a home-packed 10 cm × 75 μm, 1.8 μm C18 particle, 
home-pulled packed emitter, coupled to Q-Exactive Plus 
instrument (Thermo Fisher Scientific, MA, USA). 15 min 
loading at 0.4 μl/min, 2% organic (acetonitrile; 0.05% ace-
tic acid) was followed by a 120 min linear gradient to 50% 
organic, and 80% wash; 2% equilibration completed the 
method. MS1 scan range was 300–1650, AGC 3 × 106 and 
max ion time 60 ms. Data were processed in MaxQuant ver-
sion 1.5.6.5 [23] with Uniprot mouse reference proteome and 
normalized LFQ was generated with match-between-runs 
enabled.
Cell culture
SKBR3 and MDA-MB-231 human breast cancer cell lines 
were purchased from the American Type Culture Collec-
tion and grown in Dulbecco’s Modified Eagle’s medium 
supplemented with 2 mM l-glutamine and 10% FBS. Cells 
were maintained at 37 °C in a humidified atmosphere with 
5%  CO2. To generate stable cell lines, SKBR3 cells were 
nucleofected with 1 μg pCMV6-AC-GFP or pCMV6-AC-
GFP-HMOX1 (RG200463; Origene, MD, USA). Cells con-
taining the appropriate plasmid were selected using 600 μg/
ml G418 for 3 weeks, then FACS sorted.
AlamarBlue assay
Cells were seeded in 96-well plates and allowed to attach 
for 24 h. Escalating doses of lapatinib (GlaxoSmithKline, 
UK) or sapatinib (AZD8931; AstraZeneca, UK) prepared 
in DMSO were then added. After 72 h, AlamarBlue cell 
viability reagent (ThermoFisher Scientific, MA, USA) was 
added and fluorescence measured after a further 60 min. 
Mean values were calculated from six replicate wells and 
normalized against the mean value of the vehicle-treated 
wells. GI50 values were generated using Prism (GraphPad, 
CA, USA) from a minimum of four biological repeats.
Cell death assay
Cells were seeded in 12-well plates and allowed to attach 
for 24 h. Lapatinib (5 μM in DMSO; GlaxoSmithKline, 
UK), sapatinib (0.67 μM in DMSO; AstraZeneca, UK), 
3-methyladenine (5 mM in water; Sigma Aldrich, MO, 
USA) or bafilomycin A1 (5 nM in DMSO; Sigma Aldrich, 
MO, USA) were added to cells for 48 h. After this, cells 
were removed from dishes and 1 μg/ml propidium iodide 
(Sigma Aldrich; MO, USA) added for 5 min. Cell death 
was read on a Tali Image-based Cytometer (Invitrogen, 
CA, USA) or Accuri™ C6 Flow Cytometer (BD Bio-
sciences). All conditions were compared to DMSO control 
and single agent treatments. Statistical analysis was per-
formed using Prism (GraphPad, CA, USA) from a mini-
mum of three biological repeats.
Glucose 6 phosphate dehydrogenase (G6PD) assay
G6PD activity was measured in tissue homogenates in PBS 
using a G6PD activity assay kit based on the oxidation of 
glucose 6 phosphate to gluconolactone by G6PD, as per 
the manufacturers protocol (Abcam, Cambridge). Samples 
were measured in duplicate over 30 min and kinetic curves 
generated.
Glutathione assay
Reduced and oxidized glutathione concentration was deter-
mined in tissue homogenates using a GSH/GSSG ratio 
detection assay kit based on the detection of a fluorescent 
thiol green dye following reaction with GSH, as per the man-
ufacturers protocol (Abcam, Cambridge, UK). Samples were 
measured in duplicate.
Western blotting
Tumors were homogenized using the FastPrep-24 homogen-
iser (MP Biomedicals, CA, USA) and lysed in 1% (v/v) Tri-
ton X-100, 50 mM HEPES (pH 7.4) 150 mM NaCl, 1.5 mM 
 MgCl2, 1  mM EGTA, 100  mM NaF, 10  mM  Na4P2O7, 
1 mM  Na3VO4, 10% (v/v) glycerol,  cOmpleteTM, EDTA-
free Protease Inhibitor Cocktail and  PhosSTOPTM (Roche) 
at 4 °C. Cells were washed twice in ice cold PBS and lysed 
in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% 
TritonX-100, 0.5% sodium deoxycholate, 0.1% SDS) con-
taining  cOmpleteTM, EDTA-free Protease Inhibitor Cock-
tail and  PhosSTOPTM (Roche) at 4 °C prior to SDS-PAGE. 
Proteins were transferred to nitrocellulose and membranes 
incubated with antibodies to HO-1 (catalogue number 5853; 
1:1000), p62 (catalogue number 5114; 1:1000), pErk1/2 
(Thr202/Tyr204) (catalogue number 4370; 1:1000), Erk1/2 
(catalogue number 4696; 1:1000), pJNK (Thr183/Tyr185) 
(catalogue number 9251; 1:1000), JNK (catalogue num-
ber 9252; 1:1000) (all Cell Signaling, MA, USA) or LC3B 
(catalogue number L7543; 1:3000; Sigma Aldrich, MO, 
USA) overnight at 4 °C. Membranes were washed thrice 
with TBST before incubation with HRP-conjugated second-
ary antibodies (Cell Signaling, MA, USA1:1000). Washes 
were repeated in TBST and bound antibodies detected by 
chemiluminescence using Clarity ECL Substrate (BioRad, 
Germany) on the BioRad Gel Dox XR+.





Breast Cancer Research and Treatment 
1 3
Results
Sapatinib delays tumor progression
Tumor-bearing MMTV-NIC-PTEN+/− mice were ran-
domised to receive vehicle (1% Tween80 in PBS; po, q.d.) 
or sapatinib (100 mg/kg, with 1% Tween80 in PBS; po, 
q.d.). Vehicle-treated mice had a median survival time of 
22 days after onset of treatment, compared to 71 days for 
sapatinib-treated mice (Fig. 1a; HR: 0.3099; CI of ratio: 
0.08970–1.070; p = 0.0018). MMTV-NIC-PTEN+/− mice 
can develop multiple mammary tumors: mice treated with 
vehicle developed a median of 6 tumors each, whereas mice 
on sapatinib treatment developed a median of 5 tumors each 
(Mann–Whitney test; CI (−3)–4; p = 0.175; NS).
The index tumor was defined as the largest tumor at 
the time of sacrifice. Growth kinetics of the index tumors 
from each mouse (Fig. 1b) showed that tumors from vehi-
cle-treated mice grew rapidly after the initial tumor onset, 
whereas index tumors from sapatinib-treated mice had a 
longer period of latency after treatment commenced before 
rapid growth began. These index tumors represent tumors 
that have progressive disease in the continued presence 
of sapatinib, providing a good model with which to study 
mechanisms of resistance that models continued adjuvant 
treatment with HER2 targeted therapies given to patients.
Using RECIST guidelines [24], 83% of all tumors from 
both treatment arms combined were classed as progressive 
disease having greater than 20% increase in tumor vol-
ume (Fig. 1b; vehicle: n = 25 [92.59%]; sapatinib: n = 17 
[70.83%]). Two tumors were between 20% increase and 
30% decrease in tumor volume (Fig.  1c; vehicle: n = 0 
[0%]; sapatinib: n = 2 [8.34%]) and were thus classified as 
stable. Several tumors that became palpable after treatment 
commenced showed pathological complete response (pCR) 
to treatment, with no palpable tumor detected (Fig. 1c; vehi-
cle: n = 0 [0%]; sapatinib: n = 5 [20.84%]). Two tumors had 
partial responses, greater than 30% regression, but less than 
100% regression (Fig. 1c; vehicle: n = 1 [3.70%]; sapatinib: 
n = 1 [4.17%]). No significant difference was seen between 
treatment groups when comparing the overall percent-
age volume change from baseline (Mann–Whitney test; 
p = 0.0682; NS).
Previous work has reported that loss of PTEN can con-
fer resistance to trastuzumab and sapatinib [13, 25, 26]. 
However, analysis of PTEN in the tumors from the MMTV-
NIC-PTEN+/− mice showed that the resistant tumors did not 
result from the outgrowth of a PTEN-deficient population 
of cells following sapatinib treatment (Fig. 1d). The PI3 K/
Akt and MAPK pathways are downstream of HER2 sign-
aling. Inhibition of HER2 by sapatinib has been shown to 
reduce signaling through these pathways in MMTV-NIC-
PTEN+/− mice after 3 days of treatment with sapatinib [13]. 
To test if PI3 K/Akt and MAPK pathways remained inhib-
ited in the tumors that were able to grow through sapat-
inib treatment, immunohistochemistry was carried out for 
phospho-Akt and phospho-Erk. Levels of phospho-Akt were 
significantly reduced in sapatinib-treated tumors (Fig. 1e; 
median [CI]: vehicle: 80.18% (64.37–87.20); sapatinib: 
36.45% (31.29–80.83); p < 0.05), although no significant dif-
ference could be seen between treatment groups when com-
paring levels of phospho-Erk (Fig. 1e; median [CI]: vehicle: 
63.75% [54.93–73.13]; sapatinib: 63.22% [35.01–89.43]; 
NS). However, expression of phospho-Erk was highly vari-
able across the tumors whereas phospho-Akt expression was 
more consistent across the whole tumor section (Fig. 1e).
Proteomic analysis reveals changes in iron 
homeostasis in sapatinib‑treated tumors
To assess differentially regulated pathways in sapatinib-
treated tumors compared to vehicle-treated tumors, index 
tumors from both treatment arms were subjected to prot-
eomic analysis. This revealed a small number of proteins that 
were significantly (p < 0.05) and twofold differentially regu-
lated between vehicle-treated and sapatinib-treated tumors 
(n = 123, increased: n = 34, decreased: n = 89; Fig. 2a). Gene 
ontology (GO) analysis revealed several proteins upregu-
lated in sapatinib-treated tumors related to control of cellu-
lar iron homeostasis (n = 4; Fig. 2b; p = 0.019). In addition, 
reduced expression of proteins involved in cellular redox 
homeostasis (n = 6; p = 0.0017), response to endoplasmic 
reticulum stress (n = 7; p = 0.00028) and protein folding 
(n = 10; p < 0.00001) were identified in sapatinib-treated 
tumors compared to vehicle-treated tumors (Fig. 2b).
As cellular iron homeostasis was the only GO term 
upregulated in sapatinib-treated tumors compared to 
Fig. 1  Sapatinib increases survival in MMTV-NIC-PTEN+/− mice. 
a Kaplan–Meier survival curve showing survival time from start 
of treatment in MMTV-NIC  PTEN+/− mice treated with vehicle or 
sapatinib. Log-rank test, p = 0.0018. b Graph showing growth curves 
of index tumors in MMTV-NIC-PTEN+/− mice treated with vehicle 
or sapatinib from the onset of the first palpable tumor. c Waterfall 
plot showing volume change from baseline (%) of all MMTV-NIC-
PTEN+/− tumors from mice treated with vehicle or sapatinib. Dotted 
lines represent 20% increase, 30% decrease and 100% decrease in 
tumor volume from baseline, respectively. Two-tailed Mann–Whit-
ney test, p = 0.0682. d Representative immunohistochemical stain-
ing of PTEN (vehicle: n = 24; sapatinib: n = 12). Scale bar 50  μm. 
Quantification of PTEN staining by Definiens Architect (bottom 
panel). Results presented as mean ± standard deviation. Two-tailed 
Mann–Whitney test, not significant = NS. e Representative immu-
nohistochemical staining of phospho-Akt (vehicle: n = 11; sapatinib: 
n = 6) and phospho-Erk (vehicle: n = 25; sapatinib: n = 10). Scale bar: 
250 µm. Quantification of phospho-Akt and phospho-Erk IHC stain-
ing by Definiens Architect (bottom panels). Results presented as 
mean ± standard deviation. Two-tailed Mann–Whitney test, not sig-
nificant = NS, p < 0.05*
◂
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vehicle-treated tumors, it was decided that this represented 
a good avenue to investigate. One protein identified and 
confirmed as increased in sapatinib-treated tumors was 
HO-1 (Fig. 2c; median [CI]: non-tumor: vehicle: 23.06% 
[13.76–32.12]; sapatinib: 27.14% [21.99–46.82]; NS; 
tumor: vehicle: 14.31% [8.882–26.17]; sapatinib: 50.61% 
[23.81–73.39]; p < 0.01). Significantly higher levels of 
nuclear HO-1 were also seen in sapatinib-treated tumors 
(Fig. 2c). HO-1 has previously been linked to resistance to 
targeted- and chemo-therapies in a number of cancer types 
[27]. Due to this, we focused on the role of HO-1 in response 
to sapatinib treatment.
HO-1 is linked to the oxidative stress response and is 
a key effector of nuclear factor erythroid 2-related factor 
2 (NRF2)-mediated maintenance of redox homeostasis 
[28]. However, levels of NRF2 were lower in the sapat-
inib-treated tumors (Fig. 2d; median [CI]: vehicle: 98.05% 
[86.40–99.50]; sapatinib: 71.36% [46.39–92.96]; p < 0.01). 
Cellular oxidative stress can be measured by looking at 
the level of nicotinamide adenine dinucleotide phosphate 
(NADPH) available to provide reducing power. To meas-
ure this, we looked at the activity of glucose-6-phosphate 
dehydrogenase (G6PDH) which catalyzes the rate limiting 
step in the pentose phosphate pathway, responsible for main-
taining cellular levels NADPH [29]. Both sapatinib-treated 
and vehicle-treated tumors showed similar levels of 
G6PDH activity (Fig.  2e; slope [CI]: vehicle: 0.03973 
[0.01444–0.04502]; sapatinib: 0.02483 [0.00901–0.04066]; 
NS). Reduced glutathione (GSH) is another key cellular anti-
oxidant; increased oxidized glutathione (GSSG) is indicative 
of oxidative stress [30]. The ratio of GSH to GSSG was not 
significantly different between vehicle-treated and sapat-
inib-treated tumors (Fig. 2f; median [CI]: vehicle: 0.6186 
[0.2980–5.689]; sapatinib: 0.4666 [0.0009–1.2710]). The 
increased HO-1 in the sapatinib-treated tumors is therefore 
not linked to increased activity of an NRF-2 mediated oxida-
tive stress response.
Induction of autophagy as a mechanism 
of resistance
As HO-1 was increased in sapatinib-treated tumors and it 
has been reported to protect cells against a number of chem-
otherapeutic agents we asked whether HO-1 could protect 
cells from lapatinib and sapatinib. HO-1 was overexpressed 
in the human HER2 overexpressing breast cancer cell line 
SKBR3 (Fig. 3a). This resulted in a fivefold and fourfold 
increase in GI50 values for sapatinib and lapatinib respec-
tively (Table 1).
HO-1 has been shown to increase autophagic flux as a 
resistance mechanism in a number of tumor types [31–34]. 
Induction of autophagy in HO-1 overexpressing cells, was 
evidenced by an increased ratio of soluble microtubule-
associated protein light chain (LC3BI) to membrane bound 
LC3BII which marks the formation of autophagosomes 
(Fig. 3a). However, levels of sequestosome 1 (p62), which 
targets ubiquitinated proteins for autophagic degradation, 
were similar between empty vector and HO-1 overexpress-
ing cells (Fig. 3a). Furthermore, there was increased activa-
tion of ERK and JNK, both of which have been associated 
with autophagy regulation, in the HO-1 overexpressing cells 
(Fig. 3b).
To address whether induction of autophagy could pro-
tect cells from the effects of sapatinib and lapatinib, we 
treated cells with the autophagy inhibitors 3-methyladenine 
(3-MA) or bafilomycin A1. Treatment with either 3-MA or 
bafilomycin A had no effect on cell death (Fig. 3b; mean 
cell death% [SD]: DMSO: 10.41 [± 3.53]). Additionally, 
co-treatment of empty vector cells with sapatinib or lapa-
tinib and 3-MA or bafilomycin A1 resulted in little change 
in cell death (Fig. 3c, d; mean cell death% [SD]: DMSO: 
8.99 [± 3.00]; sapatinib: 19.44 [± 8.06]; sapatinib + 3-MA: 
18.92 [± 2.29]; sapatinib + bafilomycin: 19.68 [± 0.52]; 
lapatinib: 20.52 [± 5.92]; lapatinib + 3-MA: 18.34 [± 4.86]; 
lapatinib + bafilomycin: 16.28 [3 ± 0.26]). However, in 
HO-1 overexpressing cells autophagy inhibition signifi-
cantly increased cell death in response to both sapatinib and 
lapatinib (Fig. 3c, d; mean cell death% [SD]: DMSO: 10.41 
Fig. 2  Proteomic analysis reveals alterations in cellular iron homeo-
stasis in sapatinib-treated tumors. Index tumors from MMTV-NIC-
PTEN+/− mice treated with vehicle (n = 4) or sapatinib (n = 5) were 
subject to liquid chromatography-tandem mass spectrometry (LC–
MS/MS). Protein identification and quantitation were performed 
using MaxQuant. a Volcano plot of proteins identified by MaxQuant. 
Highlighted are proteins associated with cellular iron homeostasis, 
ferritin heavy chain (FTH), ferritin light chain (FTL), ceruloplas-
min (CP) and heme oxygenase-1 (HO-1). Dotted lines represent 
p = 0.05 and twofold ratio. b Bar chart showing significantly upreg-
ulated gene ontology (GO) terms related to proteins that were dif-
ferentially regulated between vehicle-treated and sapatinib-treated 
tumors. Dashed bars represent GO terms upregulated in sapatinib-
treated tumors, whereas solid bars represent those downregulated in 
sapatinib-treated tumors. Differentially regulated genes were selected 
as those which showed > twofold change and p < 0.05, as determined 
by MaxQuant, Wilcoxon–Mann–Whitney test. Benjamini–Hochberg 
corrected p-values and GO terms obtained from DAVID. c Repre-
sentative immunohistochemical staining of HO-1 (vehicle: n = 23; 
sapatinib: n = 9). Scale bar: 50  µm. Quantification of immunohis-
tochemical staining by Definiens Architect (bottom panels). Results 
presented as mean ± standard deviation. Kruskal–Wallis test, Dunn’s 
post hoc test, not significant = NS, p < 0.05*, p < 0.01**. d Repre-
sentative immunohistochemical staining of NRF2 (vehicle: n = 20; 
sapatinib: n = 9). Scale bar: 50  µm. Quantification of immunohis-
tochemical staining by Definiens Archtect (bottom panel). Results 
presented as mean ± standard deviation. Two-tailed Mann–Whitney 
test*, p < 0.01**. e G6PDH kinetic assay with measurements at 5 and 
30 min in vehicle (n = 4) and sapatinib-treated (n = 5) tumors. Linear 
regression, not significant = NS. f GSH/GSSG ratio determined in 
vehicle (n = 4) and sapatinib-treated (n = 5) tumors. Results presented 
as scatter plot with median ±interquartile range. Two-tailed Mann–
Whitney test, not significant = NS
◂
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[± 3.53]; sapatinib: 20.01 [± 5.97]; sapatinib + 3-MA: 29.54 
[± 9.80]; sapatinib + bafilomycin: 30.69 [± 4.70]; lapatinib: 
22.19 [± 4.70]; lapatinib + 3-MA: 28.57 [± 6.03]; lapat-
inib + bafilomycin: 35.31 [± 5.04]). Thus, in the context of 
HO-1 overexpression, autophagy is an important mechanism 
of resistance to saptinib and lapatinib-induced cell death. 
Co-treatment of MDA-MB-231 cells, which do not express 
HER2 but express EGFR, with sapatinib or lapatinib and 
3-MA or bafilomycin significantly increased cell death (Sup-
plementary Fig. 1a). Western blotting showed that HO-1 was 
not detectable in the MDA-MB-231 cells (Supplementary 
Fig. 1b). Thus, autophagy also plays a role in the sensitivity 
to both lapatinib and sapatinib in non-HER2-driven cells 
although this does not appear to be dependent on HO-1.
We then asked whether there was evidence of increased 
autophagy in the sapatinib-treated tumors. Levels of the 
autophagy-related proteins p62 and LC3B were assessed. 
Western blot analysis revealed decreased p62 in sapatinib-
treated tumors (Fig. 4a) and increased autophagic flux, evi-
denced by an increased ratio of LC3BI to LC3BII (Fig. 4a, 
b). These results were mirrored by immunohistochemical 
analysis. Sapatinib-treated tumors had lower levels of p62 
than vehicle-treated tumors (Fig. 4c, d). In addition, very few 
LC3 puncta were seen in tumors from vehicle-treated mice, 
but this was increased in the tumors that were progressing on 
sapatinib (Fig. 4d). Therefore, HO-1 expression correlates 
with autophagy induction in response to sapatinib in vivo.
Discussion
Using a HER2-driven genetically engineered mouse model 
has allowed us to identify a novel mechanism of resistance to 
HER2-targeted therapies. In this model, the initial response 
to sapatinib treatment was followed by a period of rapid 
disease progression. Analysis of tumors which were pro-
gressing while on treatment revealed a significant increase 
in HO-1. The primary role for HO-1 is in the breakdown 
of heme groups into biliverdin, releasing carbon monoxide 
and iron in the process. In addition to this homeostatic role, 
HO-1 is also induced in response to a number of cellular 
stresses in pathological conditions where it exerts strong 
antioxidant and anti-inflammatory functions. As such, 
modulation of HO-1 expression has emerged as a potential 
therapeutic target for certain cardiovascular and neurodegen-
erative diseases where it provides a cytoprotective function 
[14].
In contrast, in the context of cancer HO-1 overexpres-
sion has been reported in a number of tumor types, includ-
ing breast, where it is associated with poor prognosis [15, 
16]. Overexpression of HO-1 in experimental models has 
been shown to increase proliferation and promote survival 
of cancer cells and tumor growth in vivo although opposing 
effects have been reported suggesting tumor type specific 
effects [15, 16]. In addition, HO-1 has been implicated in 
drug- and therapy-induced resistance [17–19]. Consistent 
with these observations, our data indicate a role for HO-1 in 
resistance to sapatinib and lapatinib with HO-1 overexpress-
ing SKBR3 cells displaying a fivefold and fourfold decrease 
in sensitivity to sapatinib and lapatinib respectively. Taken 
together with the increased HO-1 in sapatinib-treated tumors 
from the MMTV-NIC-PTEN+/− mice this indicates a role 
for HO-1 in driving sapatinib resistance. Interestingly the 
increased expression of HO-1 in the sapatinib-treated tumors 
did not result from increased activity of an NRF2-mediated 
oxidative stress response. NRF2-independent induction of 
HO-1 has been reported during keratinocyte differentiation 
and muscle atrophy [35–37]. During muscle atrophy the 
NRF2-independent expression of HO-1 is driven by the tran-
scription factor FoxO1 [35]. However, as FoxO1 is activated 
by reactive oxygen species it is unlikely that the induction 
of HO-1 in the sapatinib-treated tumors is via FoxO1 and 
further work is required to delineate the pathways involved.
The mechanisms underlying resistance mediated by 
HO-1 involve induction of autophagy, response to oxi-
dative stress or a combination of both [31, 32, 38–41]. 
Here we show in the context of HER2 inhibition that the 
cytoprotective effect of HO-1 is dependent on the induc-
tion of autophagy with inhibition of autophagy enhanc-
ing both sapatinib- and lapatinib-induced cell death. The 
increased autophagy evidenced in the sapatinib-treated 
Fig. 3  Increased autophagy as a mechanism of resistance. a Western 
blot analysis of HO-1, p62 and LC3B expression in SKBR3 breast 
cancer cell lines stably transfected with a plasmid containing the 
heme oxygenase-1 (HO-1) gene or an empty plasmid. β-actin was 
used as a loading control. b Western blot analysis of SKBR3 empty 
vector and HO-1 expressing cells following treatment with DMSO, 
lapatinib or sapatinib for 2  h. c–e Cells were treated for 48  h with 
c dimethyl sulfoxide (DMSO; 0.01%), d sapatinib (0.67  µM) or e 
lapatinib (5 µM) in the presence or absence of autophagy inhibitors 
3-methyladenine (3-MA; 5  mM) or bafilomycin A1 (bafilomycin; 
5 nM). Cells were stained with propidium iodide and percentage of 
cell death was analysed using a Tali Image Cytometer. Results pre-
sented as box and whisker plot, minimum of three biological repeats. 
All conditions were compared to DMSO control and single agent 
treatments. One-way ANOVA, Bonferroni’s post hoc test, not signifi-
cant = NS, p < 0.05*, p < 0.01**, p < 0.001***
◂




Sapatinib (M)a Lapatinib (M)a
SKBR3 5.83 × 10−12 1.12 × 10−12
SKBR3 HO-1 9.53 × 10−7 4.31 × 10−8
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tumors in the MMTV-NIC-PTEN+/− mice provides fur-
ther support for HO-1-induced autophagy as a potential 
mechanism of resistance to HER2-targeted therapies. 
Several signaling pathways have been implicated in the 
induction of autophagy by HO-1 including mTOR, ERK, 




Fig. 4  Increased autophagy in tumors progressing on sapatinib. 
a Western blot analysis of p62 and LC3B in index tumors from 
MMTV-NIC-PTEN+/− mice treated with vehicle (n = 4), or sapat-
inib (n = 5). β-actin was used as a loading control. b Quantification 
of LC3BI:LC3BII. Results presented as bar graph, mean ± standard 
deviation (SD). Two-tailed Mann–Whitney test, p = 0.016. c Rep-
resentative immunohistochemical staining of p62 (vehicle: n = 22; 
sapatinib: n = 10) and LC3B (vehicle: n = 19; sapatinib: n = 8). Scale 
bar: 50 µm. Higher magnification of LC3B puncta. Scale bar: 10 µm. 
d Quantification of p62 by Definiens Architect. Results presented as 
mean ± SD, two-tailed Mann–Whitney test, p < 0.05*
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an important role in the regulation of autophagy, however, 
we were not able to detect activation of mTOR signaling 
in either the SKBR3 empty vector or HO-1 expressing cell 
lines. This is in contrast to an increased activation of ERK 
and JNK in the SKBR3 HO-1 overexpressing cells. The 
relevance of this to sapatinib resistance is not clear as we 
saw no increase in ERK activation in the sapatinib-treated 
tumors. However, a more detailed analysis of the temporal 
changes involved with these signaling pathways during the 
development of resistance will be required to understand 
the pathways involved.
Nuclear translocation of HO-1 has been demonstrated 
following its proteolytic cleavage and this can result in 
increased proliferation and invasion independent of its 
enzymatic activity [44]. Furthermore, nuclear targeting 
of HO-1 was required for its cytoprotective effects against 
imatinib [19]. This may be manifested by the activation 
of transcriptional programs by nuclear HO-1 that protect 
against oxidative stress [45, 46]. However, the role of 
nuclear HO-1 in the control of autophagy is unknown.
Several studies have shown that molecular and pharma-
cological perturbation of HO-1 can enhance drug sensitiv-
ity [17, 18, 47, 48] raising the possibility that HO-1 may 
be a potential therapeutic target [15, 16]. This has led to 
significant investment in the design and synthesis of HO-1 
inhibitors. Metalloporphyrins represent the first class of 
competitive HO-1 inhibitors that were developed: they 
compete with heme binding to HO-1 thereby reducing its 
activity. However, their clinical activity has been limited 
by off-target effects as they also interact with other heme-
containing enzymes including nitric oxide synthase, soluble 
guanylate cyclase and cytochrome P450. Although consid-
erable advances have been made to develop non-porphyrin 
inhibitors with more favorable bioavailability and increased 
selectivity for HO-1, there are limited reports of their anti-
tumor activity in vivo with potency remaining an issue [49]. 
However, our data support the future development of more 
potent and selective HO-1 inhibitors, which may provide 
additional treatment options for HER2-positive treatment 
resistant disease. Additionally, treatment with autophagy 
inhibitors presents an alternative treatment option, although 
current autophagy inhibitors in clinical trials also suffer from 
off-target effects, restricting their use [50].
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